End of Year Review 2009
Happy holidays from Future Science Group!
Everyone at Future Science Group would like to wish you happy holidays and a fantastic new year.
2009 has been a very busy and successful year for us and we would like to extend our thanks for your continued support and custom.
Over the course of the year we have launched a range of titles under our exciting new Future Science collection, as well as a host of new journals from Expert Reviews and Future Medicine, all complimented by the unveiling of our new online subscriptions service which has been very successful throughout 2009.
We are looking forward to 2010 and will be bringing you news of many great new projects coming up over the course of the year.
We are pleased to offer you a selection of some of the best articles from our latest titles launched throughout the year, which should provide you with some great holiday reading! You can find these below in our review of 2009
Best wishes,
Future Science Group
REVIEW OF 2009 - FREE ARTICLES FOR THE HOLIDAYS
A look back at our 2009 releases and a great selection of holiday reading.
2009 has been a busy year for new launches at Future Science Group. We have brought you a great selection over the last 12 months with a host of new titles from Future Medicine including Epigenomics, Imaging in Medicine, Interventional Cardiology and Immunotherapy.
In march we launched our brand new range Future Science, bringing with it 2 superb R&D focused titles; Bioanalysis and Future Medicinal Chemistry.
To celebrate the holiday season we have provided you with a selection of the best articles from our 2009 releases and a summary of our launches from the last 12 months. You will find links to download each of the articles below. You will find the articles within the folder: Best of 2009 holiday articles.
Immunotherapy
Senior Editors:
Yutaka Kawakami, Keio University School of Medicine, Japan
David C Wraith, University of Bristol, UK
Immunotherapy, launched in January 2009 offers the scientific community an interdisciplinary forum, providing them with interpretation of the most recent advances of various aspects of immunotherapeutics to aid navigation of this complex field.
Please click here to download your FREE article specially selected from Immunotherapy: Current immunotherapy for solid tumors
Bioanalysis
Senior Editors
Brian Booth, Deputy Director, food and drug administration, Division of Clinical Pharmacology 5, USA
Howard Hill, Director of Pharmaceutical Analytical Services, Huntingdon Life Sciences, UK
Bioanalysis was launched in April 2009 alongside Future Medicinal Chemistry as part of the new Future Science range. Bioanalysis is a monthly publication focusing on the development, implementation and performance of analytical technologies that enable scientists to obtain specific, selective, sensitive and reproducible data regarding a drug and its metabolites in biological samples.
Please click here to download your FREE article specially selected from Bioanalysis: Method validation and application of protein biomarkers: basic similarities and differences from biotherapeutics
Future Medicinal Chemistry
Senior Editors:
Iwao Ojima, Director of Institute of Chemical Biology and Drug Discovery, Stony Brook University, USA
David Thurston, Head of the Department of Pharmaceutical and Biological Chemistry, University of London, UK
Future Medicinal Chemistry was launched in April alongside Bioanalysis as part of the new Future Science range. Future Medicinal Chemistry delivers expert commentary and analysis on emerging research toward the establishment of new medicines- from the identification of targets, through to the synthesis and evaluation of putative therapeutic entities.
Please click here to download your FREE article specially selected from Future Medicinal Chemistry: Fluorine in medicinal chemistry: a century of progress and a 60-year retrospective of selected highlights
Epigenomics
Senior Editors:
Jorg Tost, Team Leader, Epigenetics Company Centre National de Genotypage, France
James G Herman, Associate Professor of Oncology, John Hopkins Oncology Center, USA
Epigenomics, launched in November 2009, offers a critical overview of the latest and most significant advances as they unfold and explores their potential application in the clinical setting. Through a balanced mix of original research and reviews it provides a unique forum for addressing the significant progress in this rapidly expanding research field.
Please click here to download your FREE article specially selected from Epigenomics:
Evolving role of MeCP2 in Rett syndrome and autism
Imaging in Medicine
Senior Editor:
Elliot K Fishman, Professor of Radiology & Oncology, Director, Diagnostic Imaging and Body CT, John Hopkins Hospital, USA
This new journal launched in November 2009 provides highly structured commentary and analysis regarding advanced imaging technologies and applications. It presents original research findings, publishes comprehensive profiles of imaging techniques, technologies and the materials used in the clinical and drug research settings, and explores risk issues and societal issues.
Please click here to download your FREE article specially selected from Imaging In Medicine: Radiation dose reduction in computed tomography: techniques and future perspective
Interventional Cardiology
Senior Editors:
Eberhard Grube, Chief Cardiology/Angiology, HELIOS Heart Center Siegburg, Germany
Ron Waksman, Associate Director, Division of Cardiology, and Director of Experimental Angioplasty & Emerging Technologies for the Cardiovascular Research Institute, Washington Hospital Center, USA
Interventional Cardiology, Launched in November 2009, charts the advances of this vibrant and dynamic subspecialty and provides a unique resource for interventionalists seeking to keep pace with the unfolding technologies.
Please click here to download your FREE article specially selected from Interventional Cardiology: Impact of bleeding complications on outcomes after percutaneous coronary interventions
To request a free trial for any of these titles please contact: info@futuremedicine.com
Looking ahead to 2010
A special run-down of some of our new launches for 2010.
2010 will bring with it some very exciting times for Future Science Group as well as a wave of ground breaking new titles. Most notably we will be moving into the field of environmental science for the first time with the launch of Biofuels in January and Carbon Management later in the year. We have many more exciting peices of news for you in the coming months but here we present details on our range of titles planned for launch in 2010. Check our websites and of course our E-newsletter for more information and updates on these over the coming months.
To request a free trial of the launch issue of any of these titles please contact:
info@futuremedicine.com stating your name and journal of interest.
Biofuels
Senior Editors:
Yusuf Chisti, Professor of Biochemical Engineering, Massey University, New Zealand
Timothy Donohue, Professor of Bacteriology, University of Wisconsin-Madison, USA
Biofuels provides a forum for all stakeholders in the bioenergy sector, featuring review articles, original research, commentaries, news, research and development spotlights, interviews with key opinion leaders and much more, with a view to establishing an international community of bioenergy communication.
Biofuels launches in January 2010.
Visit: www.future-science.com for more information.
Carbon Management
Carbon management captures the range of expertise and innovative enquiry represented by the diverse disciplines contributing to enhancing our comprehension of carbon interactions- from meteorology, hydrology, geology and botany to economics, land management, architecture and engineering - and disseminates their collective findings.
We will be bringing you further news on Carbon Management soon.
Check www.future-science.com for future updates.
Diabetes Management
This new journal will offer systematic coverage of the very latest advances in the treatment and prevention of diabetes mellitus, including molecular, biochemical and physiological aspects. Through a unique mixture of original research and reviews, Diabetes Management provides cutting-edge perspectives in addressing Type 1 and Type 2 diabetes.
We will be bringing you more details of Diabetes Management soon.
Check www.futuremedicine.com for future updates.
Neurodegenerative disease management
The prevention and treatment of neurodegenerative disorders represents a critical goal for current medical research teams. Bringing together the latest commentary and analysis from across a broad spectrum of practice and research, Neurodegenerative Disease Management promotes a truly multidisciplinary approach to developing new treatments for neurodegenerative diseases.
Neurodegenerative Disease Management is planned for launch in 2010. We will be bringing you more details soon, check www.futuremedicine.com for future updates.
Neuropsychiatry
This new international, peer-reviewed journal focuses on the study of mental disorders attributable to diseases of the nervous system. Through a mixture of original research, news, reviews and comment Neuropsychiatry addresses all the latest trends in the field, from R&D through to clinical application and management.
Neuropsychiatry is new in 2010. For future updates and news please check: www.futuremedicine.com
Pain Management
This peer-reviewed, multi-disciplinary journal provides a forum for commentary and debate for a growing community of pain specialists. Bringing together the latest research findings and reviews in pain medicine and pain management, this journal is a vital addition to the literature. The audience includes anesthesiologists, neurologists, physiatrists, psychiatrists, personnel working within pain clinics and other specialists with an interest in the development and application of approaches to pain management.
Pain Management is planned for release in 2010. Check www.futuremedicine.com for future updates and news stories.
Therapeutic Delivery
In a highly competitive industry, Therapeutic Delivery provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest relevant and significant developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients.
We will be bringing you more details on Therapeutic Delivery soon.
Check www.future-science.com for future updates.
Future microbiology publishes special focus issue on advances towards a systems biology understanding of pathogenic microbes
In February 2010 Future Microbiology will publish a Special Focus Issue on advances towards a systems biology understanding of pathogenic microbes. Guest Edited by Brett Finlay (UBC, Canada), Klaus Freuh (OSHU, USA) and Grant McFadden (University of Florida, USA), the issue contains the latest expert opinions and reviews on everything from protein–protein interaction studies to comparative genomics, from the use of microarray technologies to RNAi screens. World-renowned contributors include Alessandro Sette, Phil Felgner, Peter Uetz and Steve Porcella, amongst others.
The issue promises to be the definitive update on the use of systems biology in studying human microbial pathogens, and will contain must-read articles for anyone working in microbiology who wants to remain ahead of the curve and up to date with the latest advances in this booming field.
Topics covered include:
- Proteomics studies of host-pathogen interactions
- High density microarrays to study pathogens & hosts
- Defining immune epitopes in viruses
- Compatirive genomics & transcriptomics
- Studying protien-protien interactions
- Metabolomics
- Glycomics
For more information on Future Microbiology please visit: www.futuremedicine.com/loi/fmb
Personal and institutional subscriptions to Future Microbiology are also available from our secure subscriptions website.
PMC: New Study Shows That Pharmacogenomics Could Benefit Patients, Spur Investment in Innovation
Washington, D.C., August 3, 2009 -- A new study funded by the National Pharmaceutical Council (NPC) shows that pharmacogenomics -- the field of scientific research focused on learning how genetic profiles predict the body’s response to medicines – has the potential to lead to higher levels of research and development (R&D) investment and an increased pace of pharmaceutical innovation, offering substantial benefits for patients. The study, “The Future Costs, Risks and Rewards of Drug Development: The Economics of Pharmacogenomics,” was written by Joseph Cook and Graeme Hunter of NERA Economic Consulting and John Vernon of the University of North Carolina at Chapel Hill, and published in the July issue of PharmacoEconomics.
According to the study, pharmacogenomics can provide more focused and targeted information to researchers during the R&D process, potentially reducing the number of patients needed for clinical trials as well as the cost and time required to complete the trials. Products could reach the market faster, providing a longer period of time over which the innovator companies could recoup the investment costs of developing products. “We may see pharmacogenomics pushing us in the right direction of more investment in pharmaceuticals,” said study author John Vernon. “The main features likely to drive this phenomenon are the ability of pharmacogenomics to drive adoption of drugs and lower costs of development and time to commercialization. Of course, we have yet to see how these factors are likely to play out, but pharmacogenomics has the makings of a powerful force for economic change and encouraging the financing of new drugs and treatments for patients.” For example, better information about the patients who are more likely to respond to a medication could increase the rate of use of that medicine. Biological markers also could help to identify patients for whom a drug may pose a significant risk of harm. Knowing which patients are not appropriate candidates for a certain drug may help increase the likelihood that a product that might otherwise have been dropped from development could make it to market and become available to treat those patients who could benefit. Thus, as companies make decisions about products to develop, the potential for a product to generate a positive return on investment could well be affected by the improved information that pharmacogenomics can offer. As the study notes, this could have important implications for patients in the U.S. through the improved availability of new pharmaceutical and biological innovations.
The authors caution, however, that because this is such a new field of study, “there is considerable uncertainty as to how the area will evolve, both clinically and economically.” Although “the time horizon necessary for the science to develop and be adopted into clinical practice is not clear,” the study does “shed some light on possible outcomes and provides researchers with a better understanding of the economics of pharmacogenomics.” “The ability to target medicines more specifically to patient groups is a significant change in the pharmaceutical landscape,” said Dan Leonard, NPC President. “This study shows how pharmacogenomics can positively affect innovation and lead to increased benefits for patients.” NPC will continue to explore the issue of targeted, or personalized medicine, during an October 28 conference hosted in conjunction with the Personalized Medicine Coalition. Further information is available on NPC’s website, www.npcnow.org. To download a copy of the pharmacogenomics study, go to
https://articleworks.cadmus.com/doc/dSoftcopy?o=807150&i=998589&c=1472827&atDownload=true
Call for papers
If you are interested in submitting your work for publication in any of our 2009 releases or be the first to contribute to our forthcoming 2010 launches mentioned above please contact the head commissioning editor: Laura Dormer.
We strongly urge you to notify your peers and colleagues who may be interested in contributing to these ground breaking new titles and asking them to contact our launch editor.
Free Featured article
Expert Review of Clinical Immunology
Advances in the molecular imaging of multiple sclerosis
Paul M Matthews & Robert Comley
As an official subscriber to this newsletter you are able to download this article from Expert Review of Clinical Immunology for FREE.
To download this article simply...
1. Visit: www.future-science-group.com/downloads/34
2. Click: Newsletter article folder
3. Click the article and it will automatically start to download
Following this simple process will give you FREE access to this article for one month